Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/metformin - AstraZeneca

Drug Profile

Dapagliflozin/metformin - AstraZeneca

Alternative Names: Dapagliflozin/metformin FDC; Metformin/dapagliflozin; Oxramet; Xigduo FDC; Xigduo XR; Xigduo XR FDC

Latest Information Update: 07 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca
  • Class Antihyperglycaemics; Biguanides; Chlorobenzenes; Glucosides; Pyrans; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 22 May 2018 AstraZeneca completes a phase I bioequivalence trial in healthy volunteers in Brazil (NCT03216278)
  • 28 Nov 2017 AstraZeneca completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in United Kingdom (PO) (NCT03138356)
  • 28 Nov 2017 AstraZeneca terminates a phase I bioequivalence trial in healthy volunteers in Brazil, due to the need to re-design the study as subject drop-out rate during screening was too high (NCT03216278)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top